Transcriptomic profiling of kidney organoids treated with QNZ. Transcriptomic profiling of kidney organoids treated with QNZ

We performed RNA-Seq on wildtype or PDK2-null human kidney organoids treated with various concentration of QNZ or control. For WT organoid we started QNZ treatment on day8 and harvested the samples on day28. For PKD2 null organoids we started treatment on day13 and harvested the samples on day20 We performed RNA-Seq on PDK2-null human organoid derived cysts treated with various concentration of QNZ or control. We started QNZ treatment on day3 and harvest on day9. Overall design: cyst and organoid mRNA profiles of QNZ treatment vs. DMSO treatment

我们对经不同浓度QNZ或对照处理的野生型（wildtype）或PDK2敲除（PDK2-null）人类肾脏类器官开展了RNA测序（RNA-Seq）。其中，野生型类器官于第8天启动QNZ处理，并于第28天收获样本；PDK2敲除类器官则于第13天启动处理，并于第20天收获样本。此外，我们还对经不同浓度QNZ或对照处理的PDK2敲除人类类器官来源的囊肿开展了RNA测序（RNA-Seq），该处理于第3天启动，并于第9天收获样本。整体实验设计为：对比QNZ处理组与二甲基亚砜（DMSO）对照组的囊肿及类器官mRNA表达谱。